The 3-month checkpoint on a GLP-1

Where the label schedules usually are at week 12

A three-month mark sounds like a single point, but on the dose ladders it lands in different places. The table shows the earliest position each US label allows around week 12 if every step is taken on time. Many people move more slowly, because labels let prescribers delay steps when a dose is not tolerated ^[1][2][3].

Which sources set a checkpoint, and when the clock starts

Only a few official sources name a moment for judging response, and they do not count from the same starting line.

• Saxenda®, adults: the label asks for the change in body weight to be reviewed 16 weeks after starting, and for treatment to stop if less than 4% has been lost, because meaningful loss is then unlikely ^[3].
• Saxenda®, children aged 12 and older: BMI is reviewed after 12 weeks on the maintenance dose, with a 1% reduction as the bar ^[3].
• NIDDK, all weight medicines: the 12 weeks run from when you reach the full dose. If you have not lost 5% of your starting weight by then, NIDDK says your clinician will probably suggest stopping and may change the plan instead ^[5].
• Wegovy® and Zepbound®: no fixed cut-off. Both labels ask prescribers to consider treatment response and tolerability when choosing a maintenance dose ^[1][2].

What trial analyses reported at week 12

The main trials measured their results at 68 or 72 weeks, but two manufacturer-funded analyses of SURMOUNT-1 looked earlier. One included 1,545 tirzepatide users who had taken at least 75% of their doses and had weights at weeks 0, 12, 24 and 72 ^[6]. At week 12, 278 of them (18%) were still below a 5% loss. By week 24, the end of dose escalation, 70% of that group had passed 5%, and by week 72, 90% had. For these slower responders the mean time to 5% was about 25 weeks ^[6].

The slower group differed at the start: they were more often men and had higher body weight and BMI ^[6]. A second analysis, using week 8 as the dividing line, found that both early and later responders reached clinically meaningful loss at week 72, though early responders lost more ^[7].

Both analyses were post hoc, drew on a trial with regular lifestyle counselling, and left out people who lacked the needed weigh-ins ^[6][7]. They describe groups, not what will happen to you. What they do show is that week 12 sat in the middle of escalation in that trial, not at the end.

What else a three-month review can cover

Weight is one item. The labels and the nutrition advisory list other things that are worth checking at follow-up visits:

• Heart rate: the Wegovy® label asks for checks at regular intervals and for patients to report a racing heartbeat at rest ^[1].
• Eyes: people with type 2 diabetes and a history of diabetic retinopathy should be monitored for worsening, and the Medication Guide asks you to report changes in vision ^[1].
• Kidneys and fluids: the labels ask for kidney function to be checked in people whose stomach side effects could cause dehydration ^[1][2].
• Gallbladder: Wegovy® and Zepbound® report more gallstones than placebo, and the Medication Guide lists the symptoms to report ^[1][2].
• Blood sugar, if you have diabetes, and especially with insulin or a sulfonylurea ^[1].
• Eating and strength: the joint nutrition advisory asks clinicians to keep reassessing food intake and hydration, nutrient levels where needed, and muscle strength or mass during treatment ^[9].
• Lingering side effects: in the semaglutide trials constipation had a median duration of 47 days, longer than other digestive effects, so it may still be present at this point ^[8].

Questions worth bringing

• Where am I on the dose schedule, and is the next step planned, delayed or not needed?
• Which checkpoint are you using for me, and does it count from the start of treatment or from the full dose?
• Do my side effects, or the days after each dose, change the plan?
• Should my heart rate, kidney function, blood sugar or eyes be checked now?
• Is my eating and protein intake adequate, and would a dietitian or strength programme help?
• If my progress is slow, what are the options you would consider, and over what time frame?

Bringing a record rather than a feeling

The questions above are easier to answer with dates. A dose history shows whether steps were delayed or doses missed, a weight series shows the trend rather than one bad week, and symptom notes show whether side effects are fading or settling into a pattern. The Saxenda® and NIDDK checkpoints are both defined by time and weight change, so those two numbers are the core of the record ^[3][5].

Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® is a registered trademark and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.

When to get help